

Office de la Propriété Intellectuelle du Canada

Un organisme d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of Industry Canada

CA 2695678 A1 1999/04/01

(21) **2 695 678**

(12) DEMANDE DE BREVET CANADIEN CANADIAN PATENT APPLICATION

(13) **A1**

(22) Date de dépôt/Filing Date: 1998/09/22

(41) Mise à la disp. pub./Open to Public Insp.: 1999/04/01

(62) Demande originale/Original Application: 2 304 639

(30) Priorités/Priorities: 1997/09/25 (GB9720298.0); 1997/09/25 (GB9720275.8)

(51) Cl.Int./Int.Cl. *A01N 65/08* (2009.01), *A01N 25/06* (2006.01), *A01P 7/02* (2006.01), *A61L 2/00* (2006.01), *A61L 2/22* (2006.01)

(71) Demandeur/Applicant: RECKITT BENCKISER (UK) LIMITED, GB

(72) Inventeurs/Inventors:
SUH, JANETTE, US;
MCKECHNIE, MALCOLM TOM, GB;
CORNELIUS, GAY, GB;
THOMPSON, IAN ANDREW, AU

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre: AGENTS NEUTRALISANTS D'ALLERGENES D'ACARIENS DETRITICOLES

(54) Title: DEACTIVANTS FOR DUST MITE ALLERGENS

(57) Abrégé/Abstract:

Der-f and/or Der-p dust mite allergens are deactivated by an amount of one or more of the following deactivants: i) cedarwood oil, ii) hexadecyltrimethylammonium chloride, iii) aluminium chlorohydrate, iv) 1propoxy-propanol-2, v) polyquaternium-10, vi) silica gel, vii) propylene glycol alginate, viii) ammonium sulphate, ix) hinokitiol, x) L-ascorbic acid, xi) immobilised tannic acid, xii) chlorohexidine, xiii) maleic anhydride, xiv) hinoki oil, xv) a composite of AgCl and TiO2, xvi) diazolidinyl urea, xvii) 6isopropyl-m-cresol, xviii) a compound of formula (I), xix) the compound of formula (II), xx) a polymeric dialdehyde containing two or more of a recurring unit of formula (III), where n = 2 to 200, xxi) urea, xxii) cyclodextrin, xxiii) hydrogenated hop oil, xxiv) polyvinylpyrrolidone, xxv) Nmethylpyrrolidone, xxvi) the sodium salt of anthraquinone, xxvii) potassium thioglycolate, and xxviii) glutaraldehyde. Deactivants (i) to (xx) are effective against allergens derived from both species. Deactivants (xxi) to (xxvi) are effective against only Der-f allergens. Deactivants (xxvii) and (xxviii) are effective against only Der-p allergens. Aerosol compositions comprise said deactivants, a propellant and optional solvents.





Abstract

Der-f and/or Der-p dust mite allergens are deactivated by an amount of one or more of the following deactivants: i) cedarwood oil, ii) hexadecyltrimethylammonium chloride, iii) aluminium chlorohydrate, iv) 1propoxy-propanol-2, v) polyquaternium-10, vi) silica gel, vii) propylene glycol alginate, viii) ammonium sulphate, ix) hinokitiol, x) L-ascorbic acid, xi) immobilised tannic acid, xii) chlorohexidine, xiii) maleic anhydride, xiv) hinoki oil, xv) a composite of AgCl and TiO2, xvi) diazolidinyl urea, xvii) 6isopropyl-m-cresol, xviii) a compound of formula (I), xix) the compound of formula (II), xx) a polymeric dialdehyde containing two or more of a recurring 15 unit of formula (III), where n = 2 to 200, xxi) urea, xxii) cyclodextrin, xxiii) hydrogenated hop oil, xxiv) polyvinylpyrrolidone, xxv) Nmethylpyrrolidone, xxvi) the sodium salt of anthraquinone, xxvii) potassium thioglycolate, and xxviii) glutaraldehyde. Deactivants (i) 20 to (xx) are effective against allergens derived from both species. Deactivants (xxi) to (xxvi) are effective against only Der-f allergens. Deactivants (xxvii) and (xxviii) are effective against only Der-p allergens. Aerosol compositions comprise said deactivants, a propellant and optional solvents. 25

Deactivants for Dust Mite Allergens

This is a divisional patent application of Canadian Patent Application 2,304,639, filed September 22, 1998.

It has been known for a long time that house dust can trigger allergenic reactions in humans, such as asthma and rhinitis. It was reported, as early as 1928, that it was the dust mites in the dust that were the primary source of the allergenic response but it was only in the 1960's that researchers appreciated its significance.

It is believed that the faeces of two particular house dust mite species, Dermatophagoides farinae (known as Der-f) and Dermatophagoides pteronyssinus (known as Der-p) trigger the immune responses of the body, thereby giving rise to well known allergenic symptoms.

A review of this is given in Experimental and Applied Acarology, 10 (1991) p. 167-186 in an article entitled "House dust-mite allergen" : A review by L. G. Arlian.

20

Both the Der-f and Der-p species are found throughout the world. In some areas, Der-f will be the sole Dermatophagoides species. In other areas Der-p will be the sole species. In still other areas, the two species are both present through, generally, one or the other will predominate.

One way to overcome these allergenic response has

been to vacuum surfaces, such as carpets, that contain
the dust mites and their faeces thoroughly and often, but
that is both time consuming (i.e. has to be regularly
done if one wants to make an allergenic free environment)
and is very dependant on the efficiency of vacuum cleaner
and filter bag used e.g. micron filter bag or 2-layer
vacuum bags.

WO 99/15208

10

15

20

25

PCT/GB98/02863

An alternative method of creating an allergen-free environment has been to denature the allergen, for example as described in US Patent No. 4,806,526. The only effective method however of which we are aware is to apply tannic acid to the allergen. However, tannic acid can cause staining, and this is a particularly acute problem for light coloured carpets (e.g. white and light beige carpets) and other textile surfaces as tannic acid leaves a deep brown stain.

Therefore, we have been looking for allergenic dehaturants which will not stain susceptible surfaces such as carpets and still deactivate the allergen.

We have discovered a number of allergen deactivants which are effective against both the Der-f and the Der-p species. Quite surprisingly, we have discovered that some of these deactivants are specific to the type of dust mite allergen being treated. For example an effective Der-f allergen deactivants will not automatically work effectively as a Der-p allergen deactivant.

According to the invention there is provided a method for deactivating allergens derived from the Der-f and/or Der-p dust mite species, which comprises contacting the allergen with a deactivating effective amount of one or more of deactivants (herein after defined as the deactivant).

The deactivants effective against one or both of Der-f allergens and Der-p allergens are:

i) cedarwood bil,
ii) hexadecyltrimethylanmonium chloride,
iii) aluminium chlorohydrate,
iv) l-propoxy-propanol-2,
v) polyquaternium-10

	vi)	silica gel,
	vii)	propylene glycol alginate,
	viii)	ammonium sulphate,
	ix)	hinokitiol,
5	x)	L-ascorbic acid,
	xi)	"immobilised tannic acid", (hereinafter
		defined)
	xii)	chlorohexidine,
•	(iiix	maleic anhydride,
10	xiv)	hinoki oil,
	xv)	a composite of AgCl and TiOz.
	xvi)	diazolidinyl urea,
	xvii)	6-isopropyl-m-cresol,
	xviii)	a compound of formula I
	•	

$$O$$
 octyl O octyl O octyl O octyl O

15

xix) the compound of formula II

a polymeric dialdehyde containing two or more of a recurring unit of the formula III

5 where n = 2 to 200,

10

xxi) urea,

excii) cyclodextrin,

xxiii) hydrogenated hop oil,

exiv) polyvinylpyrrolidone,

xxv) N-methylpyrrolidone,

xxvi) the sodium salt of anthraquinone,

exvii) potassium thioglycolate, and

xxviii) glutaraldehyde

Deactivants (i) through (xx) are effective against both

Der-f and Der-p allergens. Deactivants (xxi) through

(xxvi) are effective against Der-f allergens only.

Deactivants (xxvii) and (xxviii) are effective against

Der-p allergens only.

A compound of formula I is commercially available as 20 Aerosol OT.

The compound of formula II is commercially available as parsley camphor.

Hinoki oil is a mixture of thujan-3-one, 2-pinene, 3,5,7,3',4'-pentahydroflavanone and 1,3,3-trimethyl-2-norcamphanone.

*Trade-mark

WO 99/15208

PCT/GB98/02863

Hydrogenated Hop Oil is the potassium salt of tetrahydroiso humulinic acid (also known as reduced isomerised hop extract).

Propylene glycol alginate is

5

Chlorohexadine is 1,1'-hexamethylenebis[5-(4-chlorophenyl)]-biguanide.

Hinokitol is β -thujaplicin, a compound of the formula

10

Germall II is diazolidinylurea.

Thymol is 6-isopropyl-m-cresol.

Cedarwood oil contains α — and β - cedrene (ca 80%), cedrol (3-14%) and cedrenol. Other sesquiterpenes and some monoterpenes are also present.

5

Polyquaternium-10 is a polymeric quaternary ammonium salt of hydroxyethyl cellulose reacted with a trimethyl ammonium substituted epoxide commercially available as Polymer JR-125*.

5 Silica gel is also known as colloidal silica or silicic acid and is commercially available as Kent*.

"Immobilised tannic acid" is tannic acid on polyvinyl pyrrolidone beads. Immobilised Tannic Acid was prepared as follows: 100 mg of tannic acid was dissolved in water; 50 mg of Polyclar 10* (ISP, Guildford Surrey) polyvinyl pyrrolidone beads were added and stirred for one hour; the beads were filtered off the solution and washed with a few mls of iced water until no colour was seen in the washings; they were then dried in the oven at 50°C.

The composite of silver chloride and ${\rm TiO_2}$ is made up of 20% wt/wt AgCl on 80% ${\rm TiO_2}$ 3-5 $\mu{\rm m}$ porous beads.

In compositions containing the deactivant, the deactivant is present in an amount of from 0.01% to 7%, preferably from 0.01% to 3%.

In methods for treating rugs and carpets to deactivate allergents, the amount of deactivant present is from about 16mg to about 170gm per 10 square meters, preferably about 32gm per 10 square meters.

Preferably the deactivant is selected from

25 xiv) hinoki oil,

xv) a composite of AgCl and TiO2,

xvi) diazolidinyl urea,

^{*}Trade-mark

		xvii)	6-isopropyl-m-cresol,
		xii)	chlorohexidine,
		xiii)	maleic anhydride,
		xxvi)	the sodium salt of anthraquinone, and
5	above, an	xviii) nd	a compound of formula I or II, defined
		xix)	a compound of formula II, defined above
		Further a	ccording to the invention there is
	provided	an aerosol	composition containing
10		i)	cedarwood oil,
		ii)	hexadecyltrimethylammonium chloride,
		iii)	aluminium chlorohydrate,
		iv)	1-propoxy-propanol-2,
		v)	polyquaternium-10,
15		vi)	silica gel,
		vii)	propylene glycol alginate,
		viii)	ammonium sulphate,
	•	ix)	hinokitiol,
		x)	L-ascorbic acid,
20	defined),		"immobilised tannic acid", (hereinafter
		xii)	chlorohexidine,
		xiii)	maleic anhydride,

xiv) hinoki oil,

xv) a composite of AgCl and TiO2,

xvi) diazolidinyl urea,

xvii) 6-isopropyl-m-cresol,

5 xviii) a compound of formula I

$$N_a^{\oplus} \ominus_{O_3S}$$
 Octyl

PCT/GB98/02863 _ WO 99/15208 the compound of formula II xix) OCH₃ a polymeric dialdehyde containing two or xx)more of a recurring unit of the formula İII CH₂OH СHО CHÓ where n = 2 to 200, xxi) urea, xxii) cyclodextrin, hydrogenated hop oil, xxiii) 10 polyvinylpyrrolidone, xxiv) (VXX N-methylpyrrolidone, the sodium salt of anthraquinone, xxvi) xxvii) potassium thioglycolate, and 15 xxviii) glutaraldehyde a propellant, and c) optionally, a solvent.

WO 99/15208

Preferably the amount of deactivant present in such a composition is from 0 01% to 7%, more preferably 0.01% to 3%,

Preferably the amount of propellant present in such a composition is from 4% to 50%, more preferably from 4% to 30%,

Preferably the amount of solvent present in such a composition is 0% to 99,95%, more preferably 0% to 90%, and most preferably from 20% to 90%.

Preferably the deactivant in such aerosol composition is selected from

hinoki oil,
a composite of AgCl with Tio,
diazolidinyl urea,

6-isopropyl-m-cresol,
chlorohexidine,
maleic anhydride,
the sodium salt of anthraguinone, and
a compound of formula I or II defined above.

Preferably the propellant is selected from those commercially available, for example C₁₋₁ alkanes, chlorofluorocarbons and compressed gases such as nitrogen, air and carbon dioxide.

Preferably the solvent is selected from C_{i-6} alcohols (e.g. ethanol) or water.

In addition, the compositions of this invention may also contain one or more of the following:

a fragrance, preferably in an amount of 0% to 5%, more preferably 0% to 2%;

WO 99/15208

an antimicrobial compound e.g. alkyldimethylbenzyl ammonium saccharinate, preferably in an amount of 0.01% to 1%;

a surfactant, e.g. Dow Corning 193 Surfactant, preferably in an amount of 0.01% to 1%;

a corrosion inhibitor, e.g. sodium nitrite, sodium benzoate, triethanolamine and ammonium hydroxide, preferably in an amount of 0.01% to 10%; and

a miticide, such as benzyl benzoate, pyrethroid pemethrin, d-allethrin and optionally a synergist such as piperonyl butoxide, preferably in an amount of 0.1% to 10%.

It has been found that deactivants of the invention have as effective allergen deactivating properties as tannic acid but without the drawback of staining.

The invention will now be illustrated by the following Examples.

Examples

The test procedure in Examples 1 to 55 is as follows and is known as the ELISA protocol.

The ELISA protocol for Der-f and Der-p has been developed as follows as a measure of denaturing property for denaturants.

25 ELISA Protocol 1

l. Dust is collected from Hoover vacuum cleaner bags and passed through a series of sieves down to 63 microns.

- 2. Clean petri dishes are labelled with the chemical to be tested (on the base). Three replicates are used for each treatment.
- 3. Filter paper is used to line each dish and 0.2g of dust is added to each dish onto the filter paper. The lid (or base, as dishes are inverted) is replaced and the dish is shaken to disperse the dust evenly over the filter paper.
 - 4. 2% aqueous solutions of deactivant were used except for the silver chloride composite where 0.5% was used
- instead. Immobilised tannic acid was used as a 1% dispersion. The hydrogenerated hop end was used at the 2% level (in the form of a 10% solution). Water-insoluble deactivants were emlulsified with a sorbitone oleate surfactant (i.e. Tween). Hinokitiol was used at 0.5% not 2%.
- The dust is sprayed with the corresponding treatment, 2 sprays are required for sufficient coverage (1 spray = 1.5 ml).
- 6. Leave uncovered at room temperature, in well aerated room, until filter paper is dry. This can take up to 4 hours.
 - 7. Empty dust in epindorfs labelled according to treatment.
 - 8. Add 1 ml of 5% Bovine Serum Albumen Phosphate
 Butter Saline Tween* BSA-PBS-T to each epindorf (5 times
 the weight of dust) (20 ml of BSA-PBS-T =1 g of BSA in 20 ml
 of PBS-T).
 - 9. Leave overnight in a refrigerator.
 - 10. Centrifuge for 5 minutes at 13,000 rpm.
 - *Trade-mark

WO 99/15208

25

- 11. Decant the supernatant into a new epindorf labelled according to treatment.
- 12. Centrifuge again for 5 minutes at 13,000 rpm.
- 13. Make up dilutions of 1:10 and 1:100 by adding 100 μ l of neat solution to 900 μ l of 1% BSA-PBS-T (1:10). This is repeated using 100 μ l of 1:10 dilution and add to 900 μ l of 1% BSA-PBS-T for 1:100 dilution.

ELISA Protocol 2 for Der-f and Der-p: Indoor Biotechnologies

- 10 1. Prepare samples and dilutions as in protocol
 - 2. Prepare 500 ml of 50 mM carbonate/bicarbonate buffer by dissolving 0.795g Na₂CO₃ and 1.465g NaHCO₃ in 500 ml of distilled water. Check the pH is at 9.6. (This solution is kept in the refrigerator in a conical flask).
- 15 3. Monoclonal antibody (kept in the freezer) has to be added to the buffer using the following method, (1 μ g per well; 11 ml is needed) applied to the ELISA plate
 - 11ml of carbonate/bicarbonate buffer is added to the dispensing tray.
- 20 11µl of Der fl or Der-pl monoclonal antibody

(Stored in freezer, epindorf in use is in the refrigerator) is added to the buffer. To ensure that all the antibody is removed from the tip, wash out the pipette tip by sucking up and down I the buffer solution, gently stirring to mix thoroughly.

4. Pipette 100 µl of the antibody solution into each well of the microtiter plate, cover with a plate sealer and leave overnight at 4°C.

WO 99/15208

- 5. Empty the place by quickly inverting it over the sink, then dry by banging on a stack of paper towels.
- 6. Add 200 μ l of wash buffer to each well: PBS/0/05% tween (PBS-T).
- 7. Repeat stages 5 and 6 once more (making a total of 2 washes).
 - 8. Make sure all the wells are dry, then add 100 µl of 1% BSA-PBS-T. Replace the plate sealer and incubate for 1 hour at room temperature*.
- 10 9. Repeat steps 5 to 7 (2 washes).
 - 10. *During the hour incubation period, prepare the allergen standards at dilutions between 125 and 1 μ g/ml Der f l or Der pl:
- Add 25 µl of allergen standard (kept in the refrigerator in polystyrene box) to 475 µl of 1% PBS-BSA-T and mix thoroughly labelled '125'.
 - 250 μ l of 1% PBS-BSA-T is added to 7 further epindorfs which are labelled 62.5, 31.25, 15.63, 7.61, 3.9, 1.95 and 0.98.
- 250 μl is taken from the 1st epindorf (labelled 125) and transferred to the next (labelled 62.5).

 This is mixed thoroughly.
- Using a new pipette tip, 250 μl is removed from epindorf labelled 62.5 and transferred to 31.25, this procedure is continued down to the 0.98 concentration (125, 62.5, 31.25, 15.63, 7.61, 3.9, 1.95, 0.98)
 - In total $475 + (250 \times 7) = 2.3ml : 0.023g of BSA added to 2.3 ml of PBS-T.$

WO 99/15208

- 11. Add 100µl aliquots of the allergen sample to the plate along with the standard allergen samples for the reference curve in duplicate. The standards usually go in the first two columns on the left hand side, with the least concentrated on top. Incubate for 1 hour.
- 12. Follow stages 5 to 6, completing a total of 5 washes.
- 13. Pour 11 ml of 1% BSA-PBS-T(0.11g of BSA to 11ml of PBS-T) to the dispensing tray. Add 11 µl of the biotinylated monoclonal antibody (refrigerator) and mix thoroughly.
 - 14. Pipette 100 μ l interestable and incubate for labour at room temperature.
- 15. Empty plate and wash as described in stage 12. (5 washes).
 - 16. Add 11 μ l of StrepEavidin (freezer) to 11 ml of 1%BSA-PBS-T. Pipette 100 μ l into each well and incubate for 30 minutes. Reserve any remaining solution in a vial.
- 20 17. Empty plate and wash as described in stage 12 (5 washes).
 - 18. Make a solution of OPD, by putting the two tablets (in silver and gold foil) into 20 ml of distilled water (in a glass vial). Shake quite vigorously in the dark until the tablets have dissolved (Wrap the vial up either in tin foil or paper towel).
 - 19. Add a small amount to the remaining solution from stage 16. Wait for a colour change (positive reaction). Add 200 µl to each well and incubate for a minimum of 30 minutes in the dark.

WO 99/15208

20. Read the plate at 450nm/405nm if filter not available.

Examples 1 to 26

The deactivants, as set out in the following table,

were used against Der-f allergens according to the above procedure and the results are as given below. Tannic acid was used as a comparator. What was measured after treatment with deactivant and tannic acid was the amount of allergen remaining active after treatment. The ratio of amount of remaining active allergen after treatment with deactivant and tannic acid is also given.

WO 99/15208

	XXI	×		xxii			≥	3	>	XXIII		XXIV 	1554	
active altergen after Deactivant/Tannic Acid Treatment	2.500	2.409	2.400	2.265	2.264	2.233	2.194	2,183	7	7		717	10.	
Allergen remaining active after tannic acid	1500	550			1800	750	1800	933.5	2000	550	1700	1425	1700	
Amount of Allergen remaining active after deactivant treatment	0366	3730	このでし	2001	J630	4075	0501	2017.5	4335	1100	3175	2450	2750	
Deactivant		1 Ires	- Polymeric dialestyde	Codarwood oil	Curlodexitin	hexadecyltrimethylamnonium chloride	Aluminium chlorohydrate	1-propoxy-propanol-2	Silica Gel (Kent)	polyquaternium-10 (Polymer JK-122)	Hydrogenated Hop UII		Poly vinyl pyrrolidone	Ammonium sulphate
Example						5 0	9		000	6	0		12	13

SUBSTITUTE SHEET (rule 26)

WO 99/15208

			······ ,			1		- ,			 1			
	×	XXV	×	· 	XVIII	XII	xix	xiii	XXVI	xiv	Χ×	xvi	xvii	
Ratio of remaining active allergen Active allergen Deactivant/Tannic Acid Treatment	1.533	1.362	1.333	1.319	1.298	0	0 883	0.875	0.765	0.739	0.719	0.685	0.523	
Amount of Altergen remaining active after tannic acid treatment	2000	1175	1500		1175									
Amount of Allergen remaining active after deactivant treatment	3065	1600	0000	1550	200		5.7141	7 6161	0231	2001	5001	050	775	
Deactivant		Hinokilo! (0.5%)	N-methyl pyrrolidone	L. Ascorbic Acid	Immobilised Tannic Acid	Aerosoi OT	Chlorahexidine	Parsley Camphor	Maieic anhydride	Anthraquinone sodium sult	Hinoki oil	Composite of AgCl and TiO,	Germall II	Thymol
Example		14	15	9]	- 1	8	61	20	21	22	23	24	25	26

SUBSTITUTE SHEET (rule 26)

WO 99/15208

PCT/GB98/02863 -

Examples 27 to 47

The deactivants, as set out in the following table, were used against Der-p allergens according to the above procedure and the results are as given below. What was measured were the amount of allergens remaining after treatment with deactivant and the amount of allergens remaining after vacuuming with no deactivant treatment.

WO 99/15208

						T-	<u> </u>	-	1	· 1	7	7	
Deactivant		1	××		= ::		- 1	7 7) is	- - -	╼╁┈		
	Allergen remaining after no deactivant treatment	3375	3375	COUP	274	4774	7664	4776	0200	0770	DC70	CICC	
Amount of active Allergen	remaining after deactivant treatment	816	2792	3375	2863	878	1233	1540	5463	3781	23.25	3002	
	Deactivant		Glutaraldehyde	Polymeric dialdehyde	Cedarwood oil	hexadecyltrimethylammonium cutulius	A luminium chlorohydrale	1-propoxy-propanol-2	Silica Gel (Kent)	polyquaternium-10 (Folymer 317-12-7)	Propylene glycol alginate	Ammonium sulphate	Potassium thioglycolate
Table	Example			2	~	4		0	7	~	6	0	17

19

PCT/GB98/02863

WO	99/15208

				<u> </u>	<u> </u>							
Deaclivant		ïX	×	×	XVIII	×			++		XVII	
Amount of	Allergen remaining after no deactivant treatment	3375	5642	5642	5642	4450	4450	4450			3400	
A llargon remaining	<u>-</u>	2058	1438	11.25		2281	2581	783	1944	1632	1500	
	Deactivant		Hinokitol (0.5%)	1-Ascorbic Acid	Immobilised Tannic Acid	Aerosol OT	Chlorohexidine	Parsley Camphor	-Maleic anhydride	Ì	Composite of AgCl and TiO;	Thymal
	Example		12	7 7	77	- -	10	2		13	20	21

SUBSTITUTE SHEET (rule 26)

Examples 48-55

Further samples were tested as above and compared against tannic acid. The ratio of actives remaining after deactivant treatment and actives remaining after tannic acid treatment are given below:

Example	Deactivant	1/Ratio of actives remaining after deactivant treatment over those remaining after tannic acid treatment	Number
48	Germall II	1.5	vi
49	N-methyl pyrrolidone	4.0	XV
50	Hinoki Oil	4.0	iv
51	Silver chloride/TiO2	3.5	V
52	Thymol	4.0	vii
53	Chlorohexidine	3.0	ii
54	Maleic anhydride	1.0	iii
55	Glutaraldehyde	1.5	xviii

Examples 56-59

The following formulations can be made up as carrier compositions for use in an aerosol for deactivating

10 Der-f and Der-p allergens

WO 99/15208

PCT/GB98/02863

Example 56

Raw Ingredient Description By Weight	Item Classification	3
Anhydrous Ethanol (SD Alcohol 40)	Solvent	79.646
Alkyl dimethyl benzyl ammonium saccharinate	Cationic Surfactant	0.106
Corrosion Inhibitor (I)		0.192
Corrosion Inhibitor (II)		0.192
Corrosion Inhibitor (III)		0.096
Deionized Water	Water/Solvent	15.768
Carbon Dioxide	Propellant	4.000
TOTAL		100.000

WO 99/15208

Example 57

Raw Ingredient	Ite	n Classification	<u>*</u>
Description by Weight			
Anhydrous Ethanol (SD	Sol	vent	* 57.000
Alcohol 40)			
Fragrance#17	Fra	grance	0.0500
	•		
Dow Corning 193	Sur	factant	0.025
Surfactant			
Corrosion Inhibitor (I)		· ·	0.100
Corrosion Inhibitor (II)			0.100
Deionized Water	Wat	er/solvent	* 14.725
NP-40/Butane 40	Hy	rocarbon	28.000
	pr	pellant	
TOTAL			100.000

^{* =} May replace with 95% Ethanol (SD Alcohol 40) at 61.755% by weight and 9.970% by weight Deionized water

WO 99/15208

PCT/GB98/02863

Example 58

Raw Ingredient	Item Classification	35
Description by Weight		
Anhydrous Ethanol (SD Alcohol 40)	Solvent	79.646
Benzyl Benzoate - an acaricide	Active/ester	4.600
Alkyl dimethyl benzyl ammonium saccharinate	Cationic Surfactant	0.106
Corrosion Inhibitor(I)		0.192
Corrosion Inhibitor (II)		0.192
Corrosion Inhibitor (III)		0.096
Deionized Water	Water/solvent	11.168
Carbon Dioxide	Propellant	4.000
TOTAL		100.000

PCT/GB98/02863

Example 59

WO 99/15208

Raw Ingredient	Item Classification	1 3
-		
Description by weight		
Nabrata Ethanal (CD	Solvient	÷57.000
Anhydrous Ethanol (SD Alcohol 40)		
ATCOMOT 40)		
Benzyl Benzoate	Active/ester	4.600
Derry At Derry Corce		
Fragrance#17	Fragrance	0.0500
t. Toral action and a		
Dow Corning 193	Surfactant	0.025
Surfactant		
Corrosion Inhibitor (I)		0.100
Corrosion Inhibitor (II)		0.100
Deionized Water	Water/solvent	*10.125
NP-40/Butane 40	Hydrocarbon propellant	28.000
	propellant	
TOTAL		100.000

weight and 5.370% by weight Deionized water.

■ May replace 95% Ethanol (SD Alcohol 40) at 61.755% by

25448-138D

CLAIMS:

10

- 1. A method for deactivating a Der-f and a Der-p allergen present on a textile surface comprising contacting the allergen with a deactivating effective amount of immobilized tannic acid.
- 2. A method for deactivating an allergen deriving from a Der-f or a Der-p dust mite, said allergen being associated with faecal particles excreted by said mites on a surface of a fabric material comprising a rug, a carpet or upholstered furniture, which method comprises applying immobilized tannic acid to said fabric material.
 - 3. An aerosol composition comprising immobilized tannic acid.
- 4. The composition according to claim 3 in which the amount of immobilized tannic acid is from 0.01% to 7%, the amount of propellant present is from 0.05% to 3%, and the amount of solvent present is from 90% to 99.95%, all percentages being by weight.
- 5. The composition according to claim 3 or 4 wherein the propellant is a C_{1-4} alkane or carbon dioxide.
 - The composition according to claim 3 to 5 wherein the solvent is a C_{1-6} alcohol or water.
 - 7. The composition according to claim 6 wherein the solvent is ethanol.
- The composition according to any one of claims 3 to 7 which further comprises at least one of the following:
 - a fragrance;
 - a surfactant

25448-138D

an antimicrobial agent,

a corrosion inhibitor, or

a miticide.